Designing a new generation of antidepressant drugs

Acta Psychiatrica Scandinavica

Volumn 96, Issue SUPPL.391, 1997, Pages 7-13

  Pinder, R M ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Antidepressants; Depression; Mirtazapine; Noradrenaline; Serotonin; Venlafaxine

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; IMIPRAMINE; IPRONIAZID; MIANSERIN; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; CYCLOPROPANE DERIVATIVE; DRUG DERIVATIVE; DULOXETINE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; SEROTONIN RECEPTOR; THIOPHENE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

CONFERENCE PAPER; DEPRESSION; DRUG DESIGN; DRUG TOLERANCE; HUMAN; NEUROTRANSMISSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SEROTONIN BLOOD LEVEL; ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; CYCLOPROPANES; DRUG DESIGN; HUMANS; MIANSERIN; MONOAMINE OXIDASE INHIBITORS; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 0030842827     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb05953.x     Document Type: Article

References (27)

1. Kalinzowsky LB, Hippims H, Klein HE. Biological treatments in psychiatry. New York: Grune & Stratton, 1982.
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965: 122: 509-522.
3. Pinder RM, Wieringa JH. Third-generation antidepressants. Med Res Rev 1993: 13: 259-325.
4. Norman TR, Leonard BE. Fast-acting antidepressants. Can the need be met? CNS Drugs 1994: 2: 120-131.
5. Broekkamp CLE, Leysen D, Peetrrs BWMM, Pinder RM. Prospects for improved antidepressants. J Med Chem 1995: 38: 4615-4633.
6. Pinder RM. Psychopharmacological profiling of antidepressants. In: Hindmarch I, Stonier P, ed. Human psychopharmacology. Measures and methods. Chichester: Wiley, 1987, vol. 1: 155-172.
7. Pinder RM. Mianserin: pharmacological and clinical correlates. Nord J Psychiatry 1991: 45(suppl 24): 13-26.
8. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994: 8: 238-249.
9. Norman TR, Burrows GD. A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Drug Safety 1995: 12: 46-54.
10. Nutt DJ, Pinder RM. O-Adrenoceptors and depression. J Psychopharmacol 1996: 10(suppl 3): 35-42.
11. Potter WZ. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. J Clin Psychiatry 1996: 57(suppl 4): 4-8.
12. Gram LF, Reisby N, Ibsen I et al. Plasma levels and clinical effects of imipramine. Clin Pharmacol Ther 1976: 19: 318-324.
13. Van Praag HM, Asnis GM, Kahn RS et al. Monoamines and abnormal behaviour. A multiaminergic perspective. Br J Psychiatry 1990: 157: 723-734.
14. Gram LF, Br0sen K, Christensen P, Kragh-S0renson P. Pharmacokinetic considerations relevant to the pharmacodynamics of antidepressants. In: Dahl SG, Gram LF, Paul SM, Potter WS, ed. Clinical pharmacology in psychiatry: selectivity in drug action, promises or problems? Heidelberg: Springer Verlag, 1987: 184-192.
15. Moret C, Charveron M, Finberg JPM, Couzinier JP, Briley M. Biochemical profile of milnacipran (F2207), 1-phenyl-l-diethylaminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985: 24: 1211-1219.
16. Von Frenckel R, Ansseau M, Serre C, Sutet P. Pooling two controlled comparisons of milnacipran (F 2207) and amitriptyline in endogenous inpatients. Int Clin Psychopharmacol 1990: 5: 49-56.
17. Palmier C, Puozzo C, Lenehan T, Briley M. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol 1989: 37: 235-238.
18. Holliday SH, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995: 49: 280-294.
19. De Boer T. The pharmacological profile of mirtazapine. J Clin Psychiatry 1996: 57(suppl 4): 19-25.
20. Leonard BE, cd. Mirtazapine-noradrenergic and specific serotonergic antidepressant (NaSSA). Hum Psychopharmacol 1995: 10(suppl2): S81-S144.
21. Mendlewioz, J. Montgomery SA. ed. Mirtazapine: a noradrenergic and specific serotonergic antidepressant. Int Clin Psychopharmacol 1995: 10(suppl 4): 3-45.
22. Clerc GE, Ruimy P, Verdhaii-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. Int Clin Psychopharmacol 1994: 9: 139-143.
23. De Boer, Neekens F, van Helvoirt A, van Delft AML. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996: 277: 852-860.
24. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996: 277: 861-871.
25. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995: 10(suppl 4): 11-17.
26. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995: 10(suppl4): 25-35.
27. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995: 10(suppl 4): 37-45.